Genetics and epigenetics of CLL

References

• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–530.
   PubMed Web of Science ®Google Scholar
• Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183–2198.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625–1638.
   PubMed Web of Science ®Google Scholar
• Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236–1242.
   PubMed Web of Science ®Google Scholar
• Queirós AC, Villamor N, Clot G, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015;29(3):598–605.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246–259.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia. 2007;21(12):2442–2451.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742–751.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-Cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323(11):720–724.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012;97(3):437–441.
   PubMed Web of Science ®Google Scholar
• Tsagiopoulou M, Chapaprieta V, Duran-Ferrer M, et al. Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. haematol. 2020;105(12):2864–2867.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Hadzidimitriou A, Sutton L-A, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329–336.
   PubMed Web of Science ®Google Scholar
• Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519–524.
   PubMed Web of Science ®Google Scholar
• Knisbacher BA, Lin Z, Hahn CK, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022;54(11):1664–1674.
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726.
   PubMed Web of Science ®Google Scholar
• Gruber M, Bozic I, Leshchiner I, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019;570(7762):474–479.
   PubMed Web of Science ®Google Scholar
• Martín-Subero JI, López-Otín C, Campo E. Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr Opin Hematol. 2013;20(4):362–368.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294.
   PubMed Web of Science ®Google Scholar
• Cheng S, Guo A, Lu P, et al. Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29(4):895–900.
   PubMed Web of Science ®Google Scholar
• Sedlarikova L, Petrackova A, Papajik T, et al. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10:894.
   PubMed Web of Science ®Google Scholar
• Gángó A, Alpár D, Galik B, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. 2020;146(1):85–93.
   PubMed Web of Science ®Google Scholar
• Liu T-M, Woyach JA, Zhong Y, et al. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126(1):61–68.
   PubMed Web of Science ®Google Scholar
• Quinquenel A, Fornecker L-M, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019;134(7):641–644.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Tian L, Anderson MA, et al. Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022;140(20):2127–2141. blood.2022016040.
   PubMed Web of Science ®Google Scholar
• Blombery P, Lew TE, Dengler MA, et al. Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022;139(8):1198–1207.
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong J, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.
   PubMed Web of Science ®Google Scholar
• Thomalla D, Beckmann L, Grimm C, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140(20):2113–2126. blood.2021014304.
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698–711.
   PubMed Web of Science ®Google Scholar
• Yan H, Tian S, Kleinstern G, et al. Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Hum Mol Genet. 2020;29(16):2761–2774.
   PubMed Web of Science ®Google Scholar
• Speedy HE, Beekman R, Chapaprieta V, et al. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat Commun. 2019;10(1):3615.
   PubMedGoogle Scholar
• Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010–1022.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Wierzbinska JA, Plass C, et al. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. Semin Cancer Biol. 2018;51:1–11.
   PubMed Web of Science ®Google Scholar
• Oakes CC, Seifert M, Assenov Y, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48(3):253–264.
   PubMed Web of Science ®Google Scholar
• Giacopelli B, Zhao Q, Ruppert AS, et al. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019;134(8):688–698.
   PubMed Web of Science ®Google Scholar
• Nadeu F, Royo R, Clot G, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021;137(21):2935–2946.
   PubMed Web of Science ®Google Scholar
• Cahill N, Bergh A-C, Kanduri M, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia. 2013;27(1):150–158.
   PubMed Web of Science ®Google Scholar
• Wahlfors J, Hiltunen H, Heinonen K, et al. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood. 1992;80(8):2074–2080.
   PubMed Web of Science ®Google Scholar
• Pan H, Renaud L, Chaligne R, et al. Discovery of candidate DNA methylation cancer driver genes. Cancer Discov. 2021;11(9):2266–2281.
   PubMed Web of Science ®Google Scholar
• Mallm J, Iskar M, Ishaque N, et al. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Mol Syst Biol. 2019;15(5):e8339.
   PubMed Web of Science ®Google Scholar
• Bechter OE, Eisterer W, Dlaska M, et al. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol. 2002;30(1):26–33.
   PubMed Web of Science ®Google Scholar
• Raval A, Lucas DM, Matkovic JJ, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005;23(17):3877–3885.
   PubMed Web of Science ®Google Scholar
• Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129(5):879–890.
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609–4614.
   PubMed Web of Science ®Google Scholar
• Calin G, Croce C. Genomics of chronic lymphocytic leukemia MicroRNAs as new players with clinical significance. Semin Oncol. 2006;33(2):167–173.
   PubMed Web of Science ®Google Scholar
• Gaiti F, Chaligne R, Gu H, et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019;569(7757):576–580.
   PubMed Web of Science ®Google Scholar
• Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011;43(8):768–775.
   PubMed Web of Science ®Google Scholar
• Oakes CC, Claus R, Gu L, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014;4(3):348–361.
   PubMed Web of Science ®Google Scholar
• Kretzmer H, Biran A, Purroy N, et al. Preneoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. Blood Cancer Discov. 2021;2(1):54–69.
   PubMedGoogle Scholar
• Vilarrasa-Blasi R, Soler-Vila P, Verdaguer-Dot N, et al. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nat Commun. 2021;12(1):651.
   PubMed Web of Science ®Google Scholar
• Prasad P, Lennartsson A, Ekwall K. The roles of SNF2/SWI2 nucleosome remodeling enzymes in blood cell differentiation and leukemia. Biomed Res Int. 2015;2015:347571–347517.
   PubMed Web of Science ®Google Scholar
• Local A, Huang H, Albuquerque CP, et al. Identification of H3K4me1-associated proteins at mammalian enhancers. Nat Genet. 2018;50(1):73–82.
   PubMed Web of Science ®Google Scholar
• Ott CJ, Federation AJ, Schwartz LS, et al. Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia. Cancer Cell. 2018;34(6):982–995.e7.
   PubMed Web of Science ®Google Scholar
• Beekman R, Chapaprieta V, Russiñol N, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24(6):868–880.
   PubMed Web of Science ®Google Scholar